Relay Therapeutics (NASDAQ: RLAY) has seen its stock surge over 344% in the past year, buoyed by promising phase 2 trial results for its drug zovegalisib, which targets vascular anomalies linked to PIK3CA mutations. The treatment demonstrated a volumetric response in about 60% of the 20 patients evaluated, expanding its potential applications beyond oncology, where it already holds breakthrough therapy designation for breast cancer. This positive data is likely to prompt investors to reassess their positions in Relay.

The company is well-capitalized with approximately $642 million in cash, providing a financial cushion to navigate the volatile biotech landscape. Relay has a structured path to market, with plans to initiate a pivotal phase 3 trial for zovegalisib in early 2027, and a diverse pipeline that includes therapies for solid tumors and rare genetic disorders. However, the biotech remains a pre-revenue entity, and any setbacks in clinical trials could significantly impact its valuation.

Investors should weigh Relay’s clinical momentum and strong financial position against the inherent risks of its developmental stage, particularly as the company’s future hinges heavily on the success of zovegalisib in upcoming trials.

Source: fool.com